VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Challenges in treating infant ALL patients with CAR-T

Colleen Annesley, MD, Seattle Children’s Research Institute, Seattle, WA, discusses the challenges of treating infant acute lymphoblastic leukemia (ALL) patients with CAR T-cell products, in particular because KMT2A-rearranged leukemia undergoing lineage switch following CD19-targeting pressure raises concern for an increased risk of myeloid leukemia relapse after B-lineage targeted CAR T-cell therapy in this population. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter